Stock NGM NGM BIOPHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company NGM Biopharmaceuticals, Inc.

Equities

NGM

US62921N1054

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:00:00 04/04/2024 BST 		5-day change 1st Jan Change
1.54 USD -1.28% Intraday chart for NGM Biopharmaceuticals, Inc. 0.00% +79.28%
04-05 NGM Biopharmaceuticals, Inc.(NasdaqGM:NGM) dropped from NASDAQ Composite Index CI
04-05 The Column Group, LLC completed the acquisition of 74% stake in NGM Biopharmaceuticals, Inc. from other group of shareholders. CI

Business Summary

NGM Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company's biology-driven and therapeutic area agnostic discovery engine has produced a diverse pipeline of product candidates spanning oncology, liver and metabolic disease and retinal disease. Its pipeline candidates include NGM707: ILT2/ILT4 Dual Antagonist Antibody for the Potential Treatment of Solid Tumors, Including microsatellite stable colorectal cancer patients; Aldafermin: Engineered Analog of Human Hormone FGF19 for the Potential Treatment of primary sclerosing cholangitis, and NGM120: glial cell-derived neurotrophic factor receptor alpha-like Antagonist for the Potential Treatment of Hyperemesis Gravidarum. It is conducting an open-label Phase 1/2 clinical trial evaluating NGM707 as a monotherapy and in combination with pembrolizumab for the treatment of patients with advanced or metastatic solid tumors. Its programs, NGM438 and NGM831, are being studied in a Phase 1/2 trial in combination with pembrolizumab.

Number of employees: 138

Managers

Managers TitleAgeSince
David Woodhouse CEO
 Chief Executive Officer 54 01/03/15
William Rieflin CHM
 Chairman 64 31/08/10
Daniel Kaplan CTO
 Chief Tech/Sci/R&D Officer - 31/12/07
William Chang CTO
 Chief Tech/Sci/R&D Officer - 31/01/19
Hsiao Lieu CTO
 Chief Tech/Sci/R&D Officer 53 28/02/19
Valerie Pierce CMP
 Compliance Officer 61 28/10/19
David Goeddel BRD
 Director/Board Member 72 31/12/07
Joyce Q. Acbay LAW
 General Counsel - 31/03/20
Irene Perlich AUD
 Comptroller/Controller/Auditor - 28/02/21

Members of the board

Members of the board TitleAgeSince
Roger Perlmutter BRD
 Director/Board Member 71 07/06/21
David Goeddel BRD
 Director/Board Member 72 31/12/07
William Rieflin CHM
 Chairman 64 31/08/10
David Woodhouse CEO
 Chief Executive Officer 54 01/03/15

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 83,462,408 81,886,322 ( 98.11 %) 0 98.11 %

Company contact information

NGM Biopharmaceuticals, Inc.

333 Oyster Point Boulevard

94080-7014, South San Francisco

+650 243 5555

http://www.ngmbio.com
address NGM Biopharmaceuticals, Inc.(NGM)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sector Bio Therapeutic Drugs

1st Jan change Capi.
NGM BIOPHARMACEUTICALS, INC. Stock NGM Biopharmaceuticals, Inc.
+79.28% 129M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. NGM Stock
  4. Company NGM Biopharmaceuticals, Inc.